Incorporation of biomarker assessment in novel clinical trial designs: Personalizing brain tumor treatments

Evanthia Galanis, Wenting Wu, Jann Sarkaria, Susan M. Chang, Howard Colman, Daniel Sargent, David A. Reardon

Research output: Contribution to journalArticle

16 Scopus citations


Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalCurrent oncology reports
Issue number1
StatePublished - Feb 1 2011



  • Adaptive design
  • Biomarker enrichment design
  • Biomarkers
  • Glioma
  • Marker by treatment interaction design
  • Neurooncology trials

ASJC Scopus subject areas

  • Oncology

Cite this